NCT02801981View on ClinicalTrials.gov

Dose-escalation Study of GSK2330672 in Japanese Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Cholestasis
Interventions
DRUG

GSK2230672

It will be supplied as white to slightly colored, round, film coated tablet for oral administration containing 10 mg or 45 mg of GSK2330672.

DRUG

Placebo

It will be supplied as placebo tablets (with no GSK2230672) visually matching to GSK2230672

Trial Locations (1)

192-0071

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02801981 - Dose-escalation Study of GSK2330672 in Japanese Healthy Male Volunteers | Biotech Hunter | Biotech Hunter